XSHE300888
Market cap3.16bUSD
Jan 17, Last price
40.18CNY
1D
2.76%
1Q
34.88%
IPO
-48.68%
Name
Winner Medical Co Ltd
Chart & Performance
Profile
Winner Medical Co., Ltd. engages in the research and development, manufacture, and marketing of cotton-based medical dressings and medical disposables, and consumer products in China. It operates through, Medical Consumables and Healthy Consumer Goods segments. The company offers wound care products, including gauze sheets, non-woven sheets, gauze bandage, dressing change kits, silicone dressings, alginate dressings, etc.; infection prevention products, such as surgical packs, surgical gowns, masks, protective clothing, isolation gowns, gloves, footwear, hats, etc.; and disinfection and cleaning products comprising cotton swabs, cotton pads, cotton balls, alcohol cotton pads, disinfectant, etc. It also offers non-woven fabric; non-woven consumer goods, such as cotton tissues, wet wipes, sanitary pads, cotton swabs, makeup cotton pads, disposable underwear, etc.; and textile consumer goods, including baby supplies and clothing, adult clothing, and other textile consumer goods. The company provides its products under the winner, Purcotton, and PureH2B brands through pharmacy chain store, hospital, e-commerce, and supermarket distribution channels. The company also sells its products to approximately 110 countries worldwide. Winner Medical Co., Ltd. was founded in 1991 and is based in Shenzhen, China. Winner Medical Co., Ltd. is a subsidiary of Winner Group Limited.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 8,185,022 -27.89% | 11,351,332 41.23% | |||||||
Cost of revenue | 7,110,265 | 8,636,637 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 1,074,757 | 2,714,694 | |||||||
NOPBT Margin | 13.13% | 23.92% | |||||||
Operating Taxes | 121,301 | 245,302 | |||||||
Tax Rate | 11.29% | 9.04% | |||||||
NOPAT | 953,456 | 2,469,393 | |||||||
Net income | 580,403 -64.84% | 1,650,717 33.20% | |||||||
Dividends | (377,764) | ||||||||
Dividend yield | 1.26% | ||||||||
Proceeds from repurchase of equity | (1) | ||||||||
BB yield | 0.00% | ||||||||
Debt | |||||||||
Debt current | 1,493,239 | 2,511,166 | |||||||
Long-term debt | 754,019 | 652,919 | |||||||
Deferred revenue | 121,649 | 98,791 | |||||||
Other long-term liabilities | 130,160 | 8,580 | |||||||
Net debt | (5,443,194) | (5,741,582) | |||||||
Cash flow | |||||||||
Cash from operating activities | 1,063,326 | 2,983,472 | |||||||
CAPEX | (753,066) | ||||||||
Cash from investing activities | 1,030,278 | ||||||||
Cash from financing activities | (1,785,427) | 1,117,507 | |||||||
FCF | 229,710 | 1,982,978 | |||||||
Balance | |||||||||
Cash | 7,556,191 | 8,905,668 | |||||||
Long term investments | 134,262 | ||||||||
Excess cash | 7,281,201 | 8,338,101 | |||||||
Stockholders' equity | 8,320,537 | 8,225,088 | |||||||
Invested Capital | 6,914,529 | 6,580,421 | |||||||
ROIC | 14.13% | 43.35% | |||||||
ROCE | 7.50% | 18.17% | |||||||
EV | |||||||||
Common stock shares outstanding | 588,293 | 587,633 | |||||||
Price | 37.25 -27.06% | 51.07 -13.28% | |||||||
Market cap | 21,913,903 -26.98% | 30,011,270 -14.53% | |||||||
EV | 17,047,806 | 24,747,850 | |||||||
EBITDA | 1,615,148 | 3,196,432 | |||||||
EV/EBITDA | 10.55 | 7.74 | |||||||
Interest | 64,428 | 50,043 | |||||||
Interest/NOPBT | 5.99% | 1.84% |